Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials

BACKGROUND: The CAIRO3 and AIO 0207 trials demonstrated the efficacy of fluoropyrimidine plus bevacizumab (FP+Bev) maintenance treatment in metastatic colorectal cancer (mCRC) patients. In this individual patient data meta-analysis with updated follow-up, we aim to provide more precise estimates of...

Full description

Bibliographic Details
Main Author: Goey, KK (author)
Other Authors: Elias, SG (author), Hinke, A (author), van Oijen, MG (author), Punt, CJ (author), Hegewisch-Becker, S (author), Arnold, D (author), Koopman, M (author)
Format: article
Language:eng
Published: 2018
Subjects:
Adenocarcinoma
Neoplasias Colorretais
Protocolos de Quimioterapia Combinada Antineoplásica
Bevacizumab
Capecitabina
Conduta Expectante
Capecitabine
Watchful Waiting
Antineoplastic Combined Chemotherapy Protocols
Colorectal Neoplasms
Online Access:http://hdl.handle.net/10400.26/23017
Country:Portugal
Oai:oai:comum.rcaap.pt:10400.26/23017

Internet

http://hdl.handle.net/10400.26/23017

Similar Items